CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sarepta Q3 revenue beats estimates

By Reuters News


Overview

  • Rare disease drugmaker's Q3 revenue fell 5% yr/yr but beat analyst expectations

  • Non-GAAP operating income and EPS turned positive on lower R&D and disciplined expenses

  • Company raised low end of FY revenue guidance and lowered high end of expense guidance


Outlook

  • Company raises 2026 net product revenue guidance to $1.25 bln-$1.3 bln

  • ELEVIDYS Q4 net product revenue expected to trend in line with Q3


Result Drivers

  • ELEVIDYS LABEL CHANGE - Co said lower ELEVIDYS sales volume was due to updated label restricting use to ambulatory patients

  • PMO FRANCHISE STRENGTH - Co cited strong PMO net product revenue as a driver for raising revenue guidance

  • CONTRACT MANUFACTURING REVENUE - Higher contract manufacturing revenue from increased ELEVIDYS supply delivered to Roche partially offset lower product sales


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$381.40 mln

$352.96 mln (19 Analysts)


Reuters Recommended Reads

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 4 - Revolution Medicines Q3 revenue reaches $198 mln after RASONQUE launch


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.